GI Cancers | Clinical

June 30, 2022

In an interview with Targeted Oncology, Charles J. Schneider, MD, FACP, provided an overview of the treatment landscape for anal carcinoma, and ongoing research.

June 28, 2022

June 21, 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the unmet needs that are hoped to be filled by the phase 1/2 KRYSTAL-1 study.

June 20, 2022

Orphan drug designation has been granted to QXL138AM for the treatment of patients with pancreatic cancers.

June 14, 2022

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor in patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

June 08, 2022

Should the primary tumor, if asymptomatic, be resected in patients with colon cancer with synchronous unresectable metastases? Study results hint that the answer is no.

June 07, 2022

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

June 07, 2022

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

June 04, 2022

Chemotherapy may be avoidable for patients with stage II colon cancer, and circulating tumor DNA has demonstrated the ability to detect which patients, according to phase 2 study results.

June 03, 2022

The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct